UBE2T

Across TCGA pan-cancer cohorts, UBE2T mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UBE2T data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE2T mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2T expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where UBE2T mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.680	0.879	.024	9	view →
LUAD	DFS	Quartile	III,IV	1.000	0.375	.013	6	view →
HNSC	OS	Median	All	0.803	0.885	.037	3	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UBE2T–PDAC (OS)

Open the PDAC breakdown →